Biography
Dr. Bilal Kazi is a Consultant Hemato-Oncologist, Cellular Therapy & BMT Physician.
He completed MBBS from P.D.V.V.P.F Medical College & Hospital, Ahmednagar, Maharashtra from 2008-2013, MD from Topiwala National Medical College & B.Y.L Nair Hospital, Mumbai, Maharashtra from 2015-2018, and DM Clinical Hematology from NRS Medical College & Hospital, Kolkata, West Bengal from 2019-2022.
He is currently working as Consultant Hemato-Oncologist, Cellular Therapy & BMT Physician at SunAct Cancer Institute, Thane from June 2024 to Present.
Academic Qualification & Clinical Experience
- MBBS – P.D.V.V.P.F Medical College & Hospital, Ahmednagar, Maharashtra – 2008-2013
- MD – Topiwala National Medical College & B.Y.L Nair Hospital, Mumbai, Maharashtra – 2015-2018
- DM Clinical Hematology – NRS Medical College & Hospital, Kolkata, West Bengal – 2019-2022
- Senior Resident, Clinical Hematology & BMT – Topiwala National Medical College & B.Y.L Nair Hospital, Mumbai – Aug 2018 – Mar 2019
- Associate Consultant, Clinical Hematology & BMT – Apollo Multispecialty Hospital, Kolkata – Sep 2022 – Apr 2024
- Consultant Hemato-Oncologist, Cellular Therapy & BMT Physician – SunAct Cancer Institute, Thane – Jun 2024 – Present
Professional Expertise & Special Skills
- CAR-T Cell Therapy
- Hands-on experience with both autologous and allogeneic CAR-T therapies
- Treated hematologic malignancies including CD19 and BCMA
- Participated in trials involving CAR-T for solid tumors
- TCR Therapy
- Experience with T-cell receptor therapy infusions for solid organ malignancies
- Bone Marrow Transplantation
- Performed over 75 autologous and allogeneic bone marrow transplants for various hematologic conditions
- T-cell harvesting
- Management of CRS and ICANS using tocilizumab and anakinra
- Utilized glofitamab as a bridging therapy before anti-CD19 CAR-T in R/R DLBCL
Research Work & Special Achievements
- Successfully managed secondary plasma cell leukemia (sPCL) with Teclistamab monotherapy in a relapsed/refractory multiple myeloma patient post-BCMA CAR-T
- Skilled in T-cell harvesting, including planning, volume calculations and complication management
- Experienced in the management of CRS and ICANS using tocilizumab and anakinra
- Utilized glofitamab (CD20/CD3 bispecific antibody) as a bridging therapy before anti-CD19 CAR-T in R/R DLBCL
Selected Publications
- Borah P, Kazi BS et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021;87:102525.
- Kazi BS. An interesting case of Langerhans cell histiocytosis. J Hematol Allied Sci. 2021;1:122-3.
- Kazi BS, et al. Pyruvate kinase deficiency case report. J Hematol Allied Sci. 2022;2:99-100.
- Kazi BS, Chakrapani A. ASH image: Hemophagocytosis. Published: 04/02/2024.
- Kazi BS, et al. Cold agglutinin syndrome from Mycoplasma pneumoniae. J Hematol Allied Sci. 2024;4:46-7.
- Bilal K, et al. EBV-induced Warm AIHA. Turk J Haematol. Published: June 28, 2024.
- Kazi B, Chakrapani A. Flame cells in IgA Myeloma. Indian J Hematol Blood Transfus. 2024.
- Kazi BS, Chakrapani A. Anaplastic Multiple Myeloma (ASH image). Published: 18/07/2024.
- Kazi BS, Shinde SV. Microfilaria in buffy coat (ASH image). Published: 22/07/2024.
- Rumani I, et al. Clinicopathological response post-NACT in LABC. J Curr Oncol Trends. 2024;1:54-62.
- Kazi B, et al. Eosinophilia masking splenic microfilariasis. Turk J Haematol. 2024;41(4):279-80.
- Kazi B, et al. Olanzapine-induced hypertriglyceridemia in cancer care. Curr Probl Cancer: Case Rep. 2024.
- Kazi B, Adallah AO, Patil V, Tembhare P, Rumani I, Kazi MNC. Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure. Turk J Haematol. Published online July 28, 2025.
- Vairamoorthy N, Kazi B, Patil V. Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. N Engl J Med. 2025;393(6):619-620.
